Stella Pharma Corporation
【Stellapharma】Share Issue and Fundraising Plan｜June 2026
Stellapharma plans to issue 1,000,000 new shares and 10,500 stock acquisition rights to the allottee through a second third-party allotment in June 2026, raising approximately ¥779 million. The funds will be allocated to clinical trials for rare and deep-seated cancers and research and development efforts.
Key Figures
- Funds raised: approximately ¥779 million
- Number of new shares issued: 1,000,000 shares
- Number of stock acquisition rights: 10,500 units
AI要約
Overview of Capital Policy
Stellapharma plans to issue new shares and stock acquisition rights to the allottee through a second third-party allotment in June 2026, raising approximately ¥779 million. The funds will be used for clinical trials and research on rare and deep-seated cancers, R&D, and overseas expansion. This aims to support future business expansion and establish a stable financial foundation. The issuance terms are set at 92% of the stock price, ensuring fair pricing. The post-issuance share dilution rate is judged to be within a reasonable range at 6.02%.
Future Outlook and Impact on Shareholders
The fundraising, with a relatively low dilution rate of 6.02%, aims to secure necessary funds for business expansion. The proceeds will be allocated to clinical trials and research on rare and deep-seated cancers, contributing to long-term corporate value enhancement. While shareholder ownership may be diluted, it is based on rationality of the fundraising and growth strategy, aiming to increase investment value.
Stellapharma Inc.
Company overview · Stock price · Financial data · All IR
